Andrei Malinovschi1*, Dora Ludviksdottir2, Ellen Tufvesson3, Giovanni Rolla4, Leif Bjermer3, Kjell Alving5 and Zuzana Diamant3,6,7,8
1Department of Medical Sciences: Clinical Physiology, Uppsala University, Uppsala, Sweden; 2Department of Respiratory Medicine and Sleep, Landspitali University Hospital, Reykjavik, Iceland; 3Department of Respiratory Medicine and Allergology, Institute for Clinical Science, Lund University, Lund, Sweden; 4Department of Medical Sciences, Allergology and Clinical Immunology, University of Torino, Torino, Italy; 5Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden; 6Department of Clinical Pharmacy & Pharmacology, University Medical Centre Groningen, Groningen, The Netherlands; 7Department of General Practice, University Medical Centre Groningen, Groningen, The Netherlands; 8QPS Netherlands, Groningen, The Netherlands
ABSTRACT
Fractional exhaled nitric oxide (FeNO) is a convenient, non-invasive method for the assessment of active, mainly Th2-driven, airway inflammation, which is sensitive to treatment with standard anti-inflammatory therapy. Consequently, FeNO serves as a valued tool to aid diagnosis and monitoring in several asthma phenotypes.
More recently, FeNO has been evaluated in several other respiratory, infectious, and/or immunological conditions. In this short review, we provide an overview of several clinical studies and discuss the status of potential applications of NO measurements in clinical conditions beyond asthma.
No comments:
Post a Comment